A phase I randomized, double-blind, dose-escalation study of OATD-01
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs OATD-01 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Sarcoidosis
- Focus Adverse reactions; First in man
- Sponsors OncoArendi Therapeutics
- 09 Oct 2017 According to an OncoArendi Therapeutics media release, the company has been granted permission from the German Federal Institute for Drugs and Medical Devices (BfArM) to begin the first-in-human clinical trial and the company will initiate this trial in this week.
- 27 Jun 2017 New trial record
- 21 Jun 2017 According to an OncoArendi Therapeutics media release, this trial is expected to begin in fall 2017.